Exelixis (EX9) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EX9 Analyst Ratings

Hold

4 Buy

10 Hold

1 Sell

Based on 15 analysts giving stock ratings to

Exelixis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EX9 Stock 12 Month Forecast

Average Price Target

€45.09

▼(-3.92% Downside)

Based on 15 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is €45.09 with a high forecast of €55.50 and a low forecast of €35.55. The average price target represents a -3.92% change from the last price of €46.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","43":"€43","56":"€56","36.5":"€36.5","49.5":"€49.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55.49630144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€55.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.090744920000006,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.55231811,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.55</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,36.5,43,49.5,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.625,47.30740780307692,47.98981560615385,48.67222340923077,49.354631212307694,50.037039015384615,50.71944681846154,51.40185462153846,52.08426242461539,52.76667022769231,53.449078030769236,54.131485833846156,54.81389363692308,{"y":55.49630144,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.625,46.50698037846154,46.388960756923076,46.27094113538462,46.15292151384615,46.034901892307694,45.916882270769236,45.79886264923077,45.68084302769231,45.56282340615385,45.44480378461539,45.32678416307693,45.208764541538464,{"y":45.090744920000006,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46.625,45.77325523923077,44.92151047846154,44.069765717692306,43.21802095692308,42.36627619615385,41.51453143538462,40.66278667461538,39.811041913846154,38.959297153076925,38.107552392307696,37.25580763153846,36.40406287076923,{"y":35.55231811,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.625,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€55.50

Average Price Target€45.09

Lowest Price Target€35.55

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and Resolution Minerals Ltd. Sponsored ADR (NASDAQ: RML)

Jason Gerberry

Bank of America Securities

€35.55

Sell

-24.24%

Downside

Reiterated

09/11/26

Analysts' Opinions Are Mixed on These NA Stocks: SpaceX (NASDAQ: SPCX), Insmed (NASDAQ: INSM) and Exelixis (NASDAQ: EXEL)

David Lebowitz

BMO Capital

€46.83

Hold

-0.22%

Downside

Reiterated

09/11/26

Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed

Stephen Willey

Stifel Nicolaus

―

Hold

―

Reiterated

09/11/26

FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating

Andy Hsieh

William Blair

―

Buy

―

Reiterated

09/11/26

Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and HEICO (NYSE: HEI)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

09/01/26

Guggenheim Remains a Hold on Exelixis (EXEL)

Etzer Darout

Barclays

€42.49

Hold

-9.46%

Downside

Reiterated

08/06/26

Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)

Eva Fortea Verdejo

Wells Fargo

€42.49→€43.36

Hold

-7.61%

Downside

Assigned

08/06/26

Exelixis (EXEL) Gets a Hold from Wells Fargo

Leonid Timashev

RBC Capital

€39.89

Hold

-15.01%

Downside

Reiterated

08/06/26

RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)

Andrew Berens

Leerink Partners

€45.09

Hold

-3.92%

Downside

Downgraded

08/06/26

Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink

Sean Laaman

Morgan Stanley

€45.96

Hold

-2.07%

Downside

Reiterated

08/06/26

Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)

Yaron Werber

TD Cowen

€47.69

Buy

1.62%

Upside

Reiterated

08/05/26

Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut

Paul Choi

Goldman Sachs

€55.5

Buy

18.25%

Upside

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Robert Burns

H.C. Wainwright

€48.56

Buy

3.47%

Upside

Reiterated

07/02/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)

Ashwani Verma

UBS

€37.29→€45.09

Hold

-3.92%

Downside

Assigned

07/02/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

―

Hold

―

Reiterated

09/14/26

Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and Resolution Minerals Ltd. Sponsored ADR (NASDAQ: RML)

Jason Gerberry

Bank of America Securities

€35.55

Sell

-24.24%

Downside

Reiterated

09/11/26

Analysts' Opinions Are Mixed on These NA Stocks: SpaceX (NASDAQ: SPCX), Insmed (NASDAQ: INSM) and Exelixis (NASDAQ: EXEL)

David Lebowitz

BMO Capital

€46.83

Hold

-0.22%

Downside

Reiterated

09/11/26

Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed

Stephen Willey

Stifel Nicolaus

―

Hold

―

Reiterated

09/11/26

FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating

Andy Hsieh

William Blair

―

Buy

―

Reiterated

09/11/26

Analysts Offer Insights on NA Companies: Exelixis (NASDAQ: EXEL) and HEICO (NYSE: HEI)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

09/01/26

Guggenheim Remains a Hold on Exelixis (EXEL)

Etzer Darout

Barclays

€42.49

Hold

-9.46%

Downside

Reiterated

08/06/26

Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)

Eva Fortea Verdejo

Wells Fargo

€42.49→€43.36

Hold

-7.61%

Downside

Assigned

08/06/26

Exelixis (EXEL) Gets a Hold from Wells Fargo

Leonid Timashev

RBC Capital

€39.89

Hold

-15.01%

Downside

Reiterated

08/06/26

RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)

Andrew Berens

Leerink Partners

€45.09

Hold

-3.92%

Downside

Downgraded

08/06/26

Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink

Sean Laaman

Morgan Stanley

€45.96

Hold

-2.07%

Downside

Reiterated

08/06/26

Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)

Yaron Werber

TD Cowen

€47.69

Buy

1.62%

Upside

Reiterated

08/05/26

Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut

Paul Choi

Goldman Sachs

€55.5

Buy

18.25%

Upside

Reiterated

08/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)

Robert Burns

H.C. Wainwright

€48.56

Buy

3.47%

Upside

Reiterated

07/02/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)

Ashwani Verma

UBS

€37.29→€45.09

Hold

-3.92%

Downside

Assigned

07/02/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months

Robert BurnsH.C. Wainwright

Success Rate

15/18 ratings generated profit

Average Return

+8.39%

Copying Robert Burns's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +8.39% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

18/18 ratings generated profit

Average Return

+37.87%

Copying Robert Burns's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.87% per trade.

2 Years

Robert BurnsH.C. Wainwright

Success Rate

18/18 ratings generated profit

Average Return

+58.84%

Copying Robert Burns's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EX9 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EX9 has received 6 Buy Ratings, 22 Hold Ratings, and 2 Sell Ratings. EX9 average Analyst price target in the past 3 months is 45.09.

Each month's total comprises the sum of three months' worth of ratings.

EX9 Financial Forecast

EX9 Earnings Forecast

Next quarter’s earnings estimate for EX9 is €0.76 with a range of €0.65 to €0.83. The previous quarter’s EPS was €0.78. EX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Sales Forecast

Next quarter’s sales forecast for EX9 is €559.40M with a range of €543.43M to €578.71M. The previous quarter’s sales results were €541.41M. EX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year EX9 has Performed in-line its overall industry.

EX9 Stock Forecast FAQ

What is DE:EX9’s average 12-month price target, according to analysts?

Based on analyst ratings, Exelixis’s 12-month average price target is 45.09.

What is DE:EX9’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:EX9, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Exelixis a Buy, Sell or Hold?

Exelixis has a consensus rating of Hold, which is based on 4 buy ratings, 10 hold ratings and 1 sell ratings.

What is Exelixis’s share price target?

The average share price target for Exelixis is 45.09. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €55.50 ,and the lowest forecast is €35.55. The average share price target represents -3.92% Decrease from the current price of €46.93.

What do analysts say about Exelixis?

Exelixis’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Exelixis?

To buy shares of DE:EX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Exelixis (EX9) Stock Forecast & Price Target

EX9 Analyst Ratings

EX9 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exelixis

EX9 Analyst Recommendation Trends

EX9 Financial Forecast

EX9 Earnings Forecast

EX9 Sales Forecast

EX9 Stock Forecast FAQ

Detailed List of Analyst Forecasts